🚀 VC round data is live in beta, check it out!
Beta Bionics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Beta Bionics and similar public comparables like IVF hartmann, Medmix, Medistim, AngioDynamics and more.
Beta Bionics Overview
About Beta Bionics
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
Founded
2015
HQ
Employees
423
Website
Sectors
Financials (LTM)
EV
$216M
Beta Bionics Financials
Beta Bionics reported last 12-month revenue of $109M and negative EBITDA of ($58M).
In the same LTM period, Beta Bionics generated $61M in gross profit, ($58M) in EBITDA losses, and had net loss of ($77M).
Revenue (LTM)
Beta Bionics P&L
In the most recent fiscal year, Beta Bionics reported revenue of $100M and EBITDA of ($53M).
Beta Bionics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $109M | XXX | $100M | XXX | XXX | XXX |
| Gross Profit | $61M | XXX | $56M | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | ($58M) | XXX | ($53M) | XXX | XXX | XXX |
| EBITDA Margin | (53%) | XXX | (53%) | XXX | XXX | XXX |
| EBIT Margin | (72%) | XXX | (72%) | XXX | XXX | XXX |
| Net Profit | ($77M) | XXX | ($73M) | XXX | XXX | XXX |
| Net Margin | (71%) | XXX | (73%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Beta Bionics Stock Performance
Beta Bionics has current market cap of $428M, and enterprise value of $216M.
Market Cap Evolution
Beta Bionics' stock price is $9.64.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $216M | $428M | -1.5% | XXX | XXX | XXX | $-1.65 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBeta Bionics Valuation Multiples
Beta Bionics trades at 2.0x EV/Revenue multiple, and (3.7x) EV/EBITDA.
EV / Revenue (LTM)
Beta Bionics Financial Valuation Multiples
As of April 11, 2026, Beta Bionics has market cap of $428M and EV of $216M.
Equity research analysts estimate Beta Bionics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Beta Bionics has a P/E ratio of (5.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $428M | XXX | $428M | XXX | XXX | XXX |
| EV (current) | $216M | XXX | $216M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | (3.7x) | XXX | (4.1x) | XXX | XXX | XXX |
| EV/EBIT | (2.7x) | XXX | (3.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | 3.9x | XXX | XXX | XXX |
| P/E | (5.5x) | XXX | (5.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Beta Bionics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Beta Bionics Margins & Growth Rates
Beta Bionics' revenue in the last 12 month grew by 33%.
Beta Bionics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Beta Bionics' rule of 40 is (21%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Beta Bionics' rule of X is 28% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Beta Bionics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 33% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Margin | (53%) | XXX | (53%) | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 32% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (21%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 62% | XXX | 61% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 30% | XXX | 31% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 35% | XXX | 35% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 127% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Beta Bionics Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| IVF hartmann | XXX | XXX | XXX | XXX | XXX | XXX |
| Medmix | XXX | XXX | XXX | XXX | XXX | XXX |
| Medistim | XXX | XXX | XXX | XXX | XXX | XXX |
| AngioDynamics | XXX | XXX | XXX | XXX | XXX | XXX |
| IBA Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Beta Bionics M&A Activity
Beta Bionics acquired XXX companies to date.
Last acquisition by Beta Bionics was on XXXXXXXX, XXXXX. Beta Bionics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Beta Bionics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBeta Bionics Investment Activity
Beta Bionics invested in XXX companies to date.
Beta Bionics made its latest investment on XXXXXXXX, XXXXX. Beta Bionics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Beta Bionics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Beta Bionics
| When was Beta Bionics founded? | Beta Bionics was founded in 2015. |
| Where is Beta Bionics headquartered? | Beta Bionics is headquartered in United States. |
| How many employees does Beta Bionics have? | As of today, Beta Bionics has over 423 employees. |
| Who is the CEO of Beta Bionics? | Beta Bionics' CEO is Sean Saint. |
| Is Beta Bionics publicly listed? | Yes, Beta Bionics is a public company listed on Nasdaq. |
| What is the stock symbol of Beta Bionics? | Beta Bionics trades under BBNX ticker. |
| When did Beta Bionics go public? | Beta Bionics went public in 2025. |
| Who are competitors of Beta Bionics? | Beta Bionics main competitors are IVF hartmann, Medmix, Medistim, AngioDynamics. |
| What is the current market cap of Beta Bionics? | Beta Bionics' current market cap is $428M. |
| What is the current revenue of Beta Bionics? | Beta Bionics' last 12 months revenue is $109M. |
| What is the current revenue growth of Beta Bionics? | Beta Bionics revenue growth (NTM/LTM) is 33%. |
| What is the current EV/Revenue multiple of Beta Bionics? | Current revenue multiple of Beta Bionics is 2.0x. |
| Is Beta Bionics profitable? | No, Beta Bionics is not profitable. |
| What is the current EBITDA of Beta Bionics? | Beta Bionics has negative EBITDA and is not profitable. |
| What is Beta Bionics' EBITDA margin? | Beta Bionics' last 12 months EBITDA margin is (53%). |
| What is the current EV/EBITDA multiple of Beta Bionics? | Current EBITDA multiple of Beta Bionics is (3.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.